NOTE

🌱 created from: treatment–curative-hnscc

keynote-689

The ongoing randomized, open-label, phase 3 KEYNOTE-689 trial is evaluating the efficacy and safety of neoadjuvant and adjuvant pembrolizumab in combination with standard-of-care (radiotherapy ± cisplatin) in patients with previously untreated, resectable, locally advanced head and neck squamous cell carcinoma, with dual primary endpoints of major pathological response and event-free survival.